Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma
— said technologies such as gene editing are fundamentally different from the drug industry's usual approach."Biotech is just beginning," Afeyan said."In the past, biotech was a little bit of bio and a little bit of tech. I think the amount of it that is bio now in terms of actually understanding has gone up and the amount of technology is incredibly higher. The result is going to be more drugs, more predictably, hopefully with less cost.
Even the most advanced gene-editing programs have provided only preliminary results. But that early data has been enough to drive further enthusiasm, reinforcing the belief that the technology can usher in a new era of drug research."We are part of this revolution in medicine to go toward one-time cures," said John Evans, CEO of the gene-editing specialist Beam Therapeutics, which commands a $6.2 billion valuation.
The scientists who discovered Crispr were awarded the Nobel Prize last year, and the public got a major introduction to Crispr's story through the biographerStill, gene-editing therapies are years away from reality, and therapies that rely on altering our genes have run into trouble before. In 1999, the field of gene therapy suffered a massive setback after the. It wasn't until 2017 that the first gene therapy was approved in the US.
Gene editing's supporters argue it is more precise and powerful than gene therapy. Some leading gene-therapy programs have faced recent setbacks over toxicity and durability concerns. While gene therapy typically uses a virus to replace a faulty gene with a working one, gene editing corrects errors in the genetic code, or DNA itself, similar to fixing a typo in a line of computer programming.
At the turn of the 21st century, the Human Genome Project completed the first rough draft of the entire genetic sequence of the human body. Since then, knowledge of human genetics has exploded, and the cost of sequencing a genome
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
9 Amazon Fashion Brands You Need to Be ShoppingAnd our edit of the best from each.
Leer más »
French Lab-Grown Meat Startup Makes Foie Gras More Appealing Than EverControversial French delicacy foie gras could see a future market expansion; as a Paris-based start-up raised $ 10 million to develop a cruelty-free and lab-grown alternative.
Leer más »
How 3 counties reached the highest COVID-19 vaccination rates in their states.ABC News spoke to officials in three counties leading their states in COVID-19 vaccinations about their campaigns, what they've done and where they go from here.
Leer más »
Derek Jeter On Signing Andy Pettitte's Son To Marlins Deal, 'He's Got Good Genes!'Does a good fastball run in Pettitte blood? Derek Jeter is certainly hoping so ... 'cause the Marlins exec said he signed Andy Pettitte's son this week because he's banking on the kid's DNA!!
Leer más »
Culture Vs. Biology: What Causes ADHD?Most researchers point to genetics and heredity as causes of ADD or ADHD. Some scientists are investigating whether certain genes, especially ones linked to the neurotransmitter dopamine, may play a role in developing attention deficit disorder. Other experts contend that our fast-paced, stressed-out, consumer-driven lives are also triggers for ADHD.
Leer más »
The Next Target for mRNA Vaccines After Covid-19: The FluIn the race to develop shots against Covid-19, mRNA vaccines beat out many traditional approaches. Now, the technology is squaring up to an old viral nemesis: influenza.
Leer más »